期刊
PATHOLOGY RESEARCH AND PRACTICE
卷 248, 期 -, 页码 -出版社
ELSEVIER GMBH
DOI: 10.1016/j.prp.2023.154619
关键词
Eye diseases; Mesenchymal stem cell (MSC); Exosome; Inflammation; Pathogenesis
类别
Mesenchymal stem cells (MSC) are considered a potential new treatment option in ophthalmology due to their unique capacity for differentiation and immunosuppressive properties. MSCs alter the phenotype and action of immune cells involved in the progression of eye inflammation through cell-to-cell contact and releasing immunomodulatory factors. Exosomes from MSCs, as natural nanoparticles, have the potential to effectively target epithelial and immune cells without interfering with nearby cells, making them a promising treatment for inflammatory eye diseases.
Because of their unique capacity for differentiation to a diversity of cell lineages and immunosuppressive properties, mesenchymal stem cells (MSC) are being looked at as a potential new treatment option in ophthalmology. The MSCs derived from all tissue sources possess immunomodulatory attributes through cell-to-cell contact and releasing a myriad of immunomodulatory factors (IL-10, TGF-13, growth-related oncogene (GRO), indoleamine 2,3 dioxygenase (IDO), nitric oxide (NO), interleukin 1 receptor antagonist (IL-1Ra), prostaglandin E2 (PGE2)). Such mediators, in turn, alter both the phenotype and action of all immune cells that serve a pathogenic role in the progression of inflammation in eye diseases. Exosomes from MSCs, as natural nanoparticles, contain the majority of the bioactive components of parental MSCs and can easily by-pass all biological barriers to reach the target epithelial and immune cells in the eye without interfering with nearby parenchymal cells, thus having no serious side effects. We outlined the most recent research on the molecular mechanisms underlying the therapeutic benefits of MSC and MSC-exosome in the treatment of inflammatory eye diseases in the current article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据